Komori
MANAC Chemical Partners (4360) · FactFirst stated

Declining sales volumes ahead of the discontinuation of certain products

First written in FY2025-H1. . Latest entry: FY2025-H1.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Sales decline due to the discontinuation of pharmaceutical API productsA theme 2 companies write about · 2 as a headwind · 0 as a tailwind

0 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2025-H1First statedAnnual report

    「In the Health Support business, domestic demand for the raw materials used in the company's mainstay pharmaceuticals for hemodialysis remained stable, but sales declined due to lower sales volumes ahead of the discontinuation of certain products.」

    In the Health Support business, domestic demand for raw materials used in pharmaceuticals for hemodialysis remained stable, while declining sales volumes ahead of the discontinuation of certain products contributed to the decrease in revenue.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
MANAC Chemical Partners's next results are scheduled for 2026-11-13. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.